-
-
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-03 Simon de Lusignan, Ting Shi, Tom Fowler, Nick Andrews, Dan Todkill, Xinchun Gu, Bernardo Meza-Torres, Chris Robertson, Aziz Sheikh
-
Vaccination hesistancy in Lyme borreliosis Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-31 Raymond J Dattwyler, Paul M Arnaboldi
-
A tribute to the elimination of leprosy Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-20 Manjulika Das
-
Managing loss during the COVID-9 pandemic Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-20 Henrietta Dunsmuir
-
The inequity in reproductive health in Brazil Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-20 Talha Burki
-
-
Virological characteristics of the SARS-CoV-2 KP.2 variant Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-20 Yu Kaku, Keiya Uriu, Yusuke Kosugi, Kaho Okumura, Daichi Yamasoba, Yoshifumi Uwamino, Jin Kuramochi, Kenji Sadamasu, Kazuhisa Yoshimura, Hiroyuki Asakura, Mami Nagashima, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Jumpei Ito, Kei Sato
-
Prevention of congenital syphilis within antenatal PrEP services in South Africa: missed opportunities Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-08 Dvora Joseph Davey, Alex de Voux, Lerato Hlatshwayo, Aurelie Nelson, Lisa Frigati, Kalisha Bheemraj, Nafisa Wara, Rufaro Mvududu, Landon Myer
-
Ceftriaxone resistance in Neisseria gonorrhoeae associated with the penA-60.001 allele in Hanoi, Viet Nam Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-06 Paul C Adamson, Vu N Hieu, Pham H Nhung, DM Whiley, TM Chau
-
Shifting transmission patterns of human mpox in South Kivu, DR Congo Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-01 Patrick DMC Katoto, Winters Muttamba, Esto Bahizire, Espoir Bwenge Malembaka, Henry Kyobe Bosa, Dieudonné Mwamba Kazadi, Gaston Lubambo, Freddy Belesi Siangoli, Barnabas Bakamutumaho, Misaki Wayengera, Don Jethro Mavungu Landu, Daniel Mukadi-Bamuleka, Placide Mbala, Mark Loeb, Bruce Kirenga, Jean-Jacques Muyembe-Tamfum
-
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-30 Flavio Finger, Kristen Heitzinger, David Berendes, Iza Ciglenecki, Morgane Dominguez, Kate Alberti, Emmanuel Baron, Philippe Barboza
-
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-30 Sonia Ares-Gómez PhD, Narmeen Mallah PhD, María-Isolina Santiago-Pérez BS, Jacobo Pardo-Seco PhD, Olaia Pérez-Martínez MD, María-Teresa Otero-Barrós MD, Nuria Suárez-Gaiche MD, Rolf Kramer PhD, Jing Jin PhD, Leticia Platero-Alonso PhD, Rosa-María Alvárez-Gil MD, Olga-María Ces-Ozores RPH, Victoria Nartallo-Penas PhD, Susana Mirás-Carballal RPH, Marta Piñeiro-Sotelo RPH, Alberto Malvar-Pintos MD, Juan-Manuel
Galicia (Spain) was one of the first regions worldwide to incorporate nirsevimab for universal respiratory syncytial virus (RSV) prophylaxis in infants into its immunisation programme. The NIRSE-GAL longitudinal population-based study aimed to assess nirsevimab effectiveness in preventing hospitalisations (ie, admittance to hospital). The 2023–24 immunisation campaign with nirsevimab in Galicia began
-
Reducing risks from respiratory pathogens at the 2024 Hajj Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-23 Ziad A Memish, Majid M Alshamrani, Rana F Kattan, Esam I Azhar, Fayssal M Farahat, Ali M Albarrak, Alimuddin Zumla
-
Community perspectives on abortion in eastern South Africa Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-22 Sylvia Warren
-
Family and sexual behaviour in South Africa Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-22 Hollie Sherwood-Martin
-
-
Listeria monocytogenes: a rare, deadly cause of peritonitis Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-09 Maria Gori
-
Listeria monocytogenes-associated spontaneous bacterial peritonitis in France: a nationwide observational study of 208 cases Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-09 Florian Blanchard MD, Benoît Henry MD PhD, Sofieya Vijayaratnam, Etienne Canouï MD, Alexandra Moura PhD, Pierre Thouvenot, Hélène Bracq-Dieye, Nathalie Tessaud-Rita, Guillaume Valès, Andrée Diakité, Alexandre Leclercq MSc, Prof Marc Lecuit MD PhD, Prof Caroline Charlier MD PhD, Listeria monocytogenes-associated Spontaneous Peritonitis Study Group, Mohamed Abdou, Ayman Abdulhai, Ayman Abdulhal, Samy
Listeriosis is a foodborne infection caused by . Three main forms of listeriosis are well characterised, but little is known about -associated spontaneous bacterial peritonitis. We used data from the French national surveillance of listeriosis to perform a nationwide retrospective study. All patients with isolated by culture from a peritoneal fluid sample in France between April 1, 1993, and Dec 31
-
Plasma-based antigen persistence in the post-acute phase of COVID-19 Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-08 Michael J Peluso, Zoe N Swank, Sarah A Goldberg, Scott Lu, Thomas Dalhuisen, Ella Borberg, Yasmeen Senussi, Michael A Luna, Celina Chang Song, Alexus Clark, Andhy Zamora, Megan Lew, Badri Viswanathan, Beatrice Huang, Khamal Anglin, Rebecca Hoh, Priscila Y Hsue, Matthew S Durstenfeld, Matthew A Spinelli, David V Glidden, Timothy J Henrich, J Daniel Kelly, Steven G Deeks, David R Walt, Jeffrey N Martin
-
-
Presence of Andes orthohantavirus in human body fluids Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-03 Alemka Markotić
-
Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-03 Prof Marcela Ferrés MD, Constanza Martínez-Valdebenito MSc, Carolina Henriquez MSc, Claudia Marco MSc, Jenniffer Angulo PhD, Aldo Barrera PhD, Carlos Palma BSc, Gonzalo Barriga Pinto PhD, Analia Cuiza RN, Leonila Ferreira MD, María Luisa Rioseco MD, Mario Calvo MD, Ricardo Fritz MD, Sebastián Bravo MD, Prof Alejandro Bruhn PhD, Jerónimo Graf MD, Alvaro Llancaqueo MD, Gonzalo Rivera MD, Carolina Cerda
Andes virus (ANDV) is a zoonotic leading to hantavirus cardiopulmonary syndrome. Although most transmissions occur through environmental exposure to rodent faeces and urine, rare person-to-person transmission has been documented, mainly for close contacts. This study investigates the presence and infectivity of ANDV in body fluids from confirmed cases and the duration of viraemia. In this prospective
-
Zoonotic tuberculosis in the 21st century Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-29 Anna S Dean, Gregorio Torres, Orr Rozov, Tereza Kasaeva
-
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-26 Ynke Larivière MSc, Trésor Zola Matuvanga MD, Bernard Isekah Osang'ir MSc, Solange Milolo MD, Rachel Meta MD, Primo Kimbulu MSCS, Cynthia Robinson MD, Michael Katwere MD, Chelsea McLean PhD, Gwen Lemey MA, Prof Junior Matangila MD PhD, Prof Vivi Maketa MD PhD, Prof Patrick Mitashi MD PhD, Prof Jean-Pierre Van geertruyden MD PhD, Prof Pierre Van Damme MD PhD, Prof Hypolite Muhindo-Mavoko MD PhD
Health-care providers and front-line workers are at risk of contracting Ebola virus disease during an Ebola virus outbreak and consequently of becoming drivers of the disease. We aimed to assess the long-term immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen and the safety of and immune memory response to an Ad26.ZEBOV booster vaccination at 1 year or 2 years after the first dose in this
-
Single dose of Dengvaxia vaccine: is it a cause for alarm? Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-22 Corazon C Buerano, Kouchi Morita
-
Post-tuberculosis lung disease: is there a light at the end of tunnel? Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-22 Jeremiah Chakaya, Razia Fatma, Mizaya Cader, Anthony D Harries
-
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort study Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-22 Michelle Ylade MD, Maria Vinna Crisostomo MD, Jedas Veronica Daag BS, Kristal An Agrupis MD, Anna Maureen Cuachin BS, Ava Kristy Sy MSc, Deok Ryun Kim PhD, Hyeon Seon Ahn MSc, Ana Coello Escoto BS, Leah C Katzelnick PhD, Cameron Adams MD, Laura White PhD, Prof Aravinda M de Silva PhD, Jacqueline Deen MD, Anna Lena Lopez
A three-dose dengue vaccine (CYD-TDV) was licensed for use in children aged 9 years and older starting in 2015 in several dengue-endemic countries. In 2016, the Philippine Department of Health implemented a dengue vaccination programme, which was discontinued because of safety concerns. We assessed the relative risk of developing virologically confirmed dengue among children who did or did not receive
-
Mycobacterium tuberculosis transmission: the importance of precision Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-22 Ryan Dinkele, Palwasha Y Khan, Digby F Warner
-
Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1 Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-21 Dhammika Leshan Wannigama, Mohan Amarasiri, Phatthranit Phattharapornjaroen, Cameron Hurst, Charin Modchang, Sudarat Chadsuthi, Suparinthon Anupong, Kazuhiko Miyanaga, Longzhu Cui, Stefan Fernandez, Angkana T Huang, Puey Ounjai, Andrew C Singer, Naveen Kumar Devanga Ragupathi, Daisuke Sano, Takashi Furukawa, Kazunari Sei, Asada Leelahavanichkul, Talerngsak Kanjanabuch, Tanittha Chatsuwan, Paul G Higgins
-
The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-19 Si-Min Li, Feng-Cai Zhu
-
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-19 Avika Dixit MBBS, Richard Bennett MD, Kashif Ali MD, Carl Griffin MD, Robert A Clifford MD, Mark Turner MD, Rosanne Poston BS, Kelly Hautzinger BS, Anne Yeakey MD, Bethany Girard PhD, Wen Zhou PhD, Weiping Deng PhD, Honghong Zhou PhD, Sabine Schnyder Ghamloush MD, Barbara J Kuter PhD, Karen Slobod MD, Jacqueline M Miller MD, Frances Priddy MD, Rituparna Das MD, ROVER Study Investigators, Kashif Ali
Variant-containing mRNA vaccines for COVID-19 to broaden protection against SARS-CoV-2 variants are recommended based on findings in adults. We report interim safety and immunogenicity of an omicron BA.1 variant-containing (mRNA-1273.214) primary vaccination series and booster dose in paediatric populations. This open-label, two-part, non-randomised phase 3 trial enrolled participants aged 6 months
-
Towards improving the quality and usefulness of GBD tuberculosis estimates Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-19 Richard G White, JVR Prasada Rao
-
Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-19 GBD 2021 Tuberculosis Collaborators, Jorge R Ledesma, Jianing Ma, Meixin Zhang, Ann V L Basting, Huong Thi Chu, Avina Vongpradith, Amanda Novotney, Kate E LeGrand, Yvonne Yiru Xu, Xiaochen Dai, Sneha Ingle Nicholson, Lauryn K Stafford, Austin Carter, Jennifer M Ross, Hedayat Abbastabar, Meriem Abdoun, Deldar Morad Abdulah, Richard Gyan Aboagye, Hassan Abolhassani, Woldu Aberhe Abrha, Hiwa Abubaker
-
-
-
A step forward in the journey towards hookworm vaccines Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-18 Jennifer Keiser, Tiffany Bouchery
-
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-18 Jeannot F Zinsou MD, Prof David J Diemert MD, Jean Claude Dejon-Agobé MD, Bayodé R Adégbité PhD, Yabo Josiane Honkpehedji MD, Kafui G Vodonou MSc, Rodrigue Bikangui MSc, Jean Ronald Edoa MD, Marguerite Massinga Loembe PhD, Guangzhao Li MS, Prof Maria Yazdanbakhsh PhD, Prof Maria Elena Bottazzi PhD, Remko van Leeuwen MD, Prof Peter G Kremsner MD, Prof Peter J Hotez PhD, Prof Jeffrey M Bethony PhD, Prof
A human hookworm vaccine is being developed to protect children against iron deficiency and anaemia associated with chronic infection with hookworms. aspartic protease-1 (-APR-1) and glutathione S-transferase-1 (-GST-1) are components of the blood digestion pathway critical to hookworm survival in the host. Recombinant -GST-1 and catalytically inactive -APR-1 (-APR-1[M74]) adsorbed to Alhydrogel were
-
The hidden threat of subclinical tuberculosis Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-12 Xiaolin Wei, Wenhong Zhang
-
Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-12 Logan Stuck PhD, Eveline Klinkenberg PhD, Nahid Abdelgadir Ali MD, Egbal Ahmed Basheir Abukaraig MD, Yaw Adusi-Poku MD, Zeleke Alebachew Wagaw MD, Razia Fatima MD, Nathan Kapata PhD, Pascalina Kapata-Chanda PhD, Bruce Kirenga PhD, Llang B Maama-Maime MD, Prof Sayoki G Mfinanga PhD, Sizulu Moyo PhD, Lindiwe Mvusi MD, Ndahafa Nandjebo RN, Hai Viet Nguyen PhD, Hoa Binh Nguyen PhD, Joshua Obasanya MD,
Subclinical pulmonary tuberculosis, which presents without recognisable symptoms, is frequently detected in community screening. However, the disease category is poorly clinically defined. We explored the prevalence of subclinical pulmonary tuberculosis according to different case definitions. We did a one-stage individual participant data meta-analysis of nationally representative surveys that were
-
Accelerating antibiotic access and stewardship: a new model to safeguard public health Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-11 Jennifer Cohn MD, Prof Marc Mendelson PhD, Prof Souha S Kanj MD, Nusrat Shafiq DM, Icaro Boszczowski MD, Ramanan Laxminarayan PhD
This Personal View discusses the challenges faced, especially by low-income and middle-income countries (LMICs), in responding to the growing burden of bacterial antimicrobial resistance. Many patients in LMICs lack access to effective and affordable treatments needed to successfully treat patients. Meanwhile, traditional antimicrobial stewardship models face implementation challenges due to financial
-
Consensus definitions in imported human schistosomiasis: a GeoSentinel and TropNet Delphi study Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-08 Francesca Tamarozzi PhD, Cristina Mazzi MSc, Prof Spinello Antinori MD, Marta Arsuaga PhD, Prof Sören L Becker PhD, Prof Emmanuel Bottieau PhD, Daniel Camprubi-Ferrer PhD, Prof Eric Caumes PhD, Alexandre Duvignaud MD, Prof Martin P Grobusch FRCP, Prof Stephane Jaureguiberry PhD, Sabine Jordan MD, Andreas Mueller MD, Andreas Neumayr MD, Jose A Perez-Molina PhD, Joaquin Salas-Coronas PhD, Fernando Salvador
Terminology in schistosomiasis is not harmonised, generating misunderstanding in data interpretation and clinical descriptions. This study aimed to achieve consensus on definitions of clinical aspects of schistosomiasis in migrants and returning travellers. We applied the Delphi method. Experts from institutions affiliated with GeoSentinel and TropNet, identified through clinical and scientific criteria
-
Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-06 Ruiqi Zhang, Ivan Fan-Ngai Hung
-
Untold Lassa fever story: a physician's lived experience Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-06 Qudus Olajide Lawal
-
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-06 Chijioke Bennett MD, Wayne Woo MS, Mark Bloch MBBS, King Cheung MD, Paul Griffin MBBS, Rahul Mohan MD, Sachin Deshmukh MBBS, Mark Arya MD, Oscar Cumming BMed, A Munro Neville MBBS, Toni G McCallum Pardey MS, Joyce S Plested PhD, Shane Cloney-Clark BS, Mingzhu Zhu PhD, Raj Kalkeri PhD, Nita Patel MS, Alex Marcheschi PharmD, Jennifer Swan BS, Gale Smith PhD, Iksung Cho MS, Gregory M Glenn MD, Robert
SARS-CoV-2 variants evade immunity despite vaccination with prototype COVID-19 vaccines or previous infection. The 2019nCoV-311 (part 2) study is evaluating immune responses after two booster doses of a vaccine containing the omicron BA.5 subvariant spike protein in adults previously vaccinated with a prototype mRNA vaccine. This interim analysis reports on day 28 immunogenicity and safety outcomes
-
A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus study Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-05 Manu P Bilsen MD, Prof Simon P Conroy PhD, Caroline Schneeberger MD, Tamara N Platteel MD, Cees van Nieuwkoop MD, Prof Lona Mody MD, Prof Jeffrey M Caterino MD, Prof Suzanne E Geerlings MD, Bela Köves MD, Prof Florian Wagenlehner MD, Marleen Kunneman PhD, Prof Leo G Visser MD, Merel M C Lambregts MD, UTI Reference Standard Consensus Group, Thomas Hooton, Lindsay Nicolle, Barbara Trautner, Kalpana Gupta
The absence of a consensus-based reference standard for urinary tract infection (UTI) research adversely affects the internal and external validity of diagnostic and therapeutic studies. This omission hinders the accumulation of evidence for a disease that imposes a substantial burden on patients and society, particularly in an era of increasing antimicrobial resistance. We did a three-round Delphi
-
Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-04 Dan-Yu Lin, Shuaiqi Huang, Alex Milinovich, Abhijit Duggal, Xiaofeng Wang
-
Progress towards safer and more effective radical cure of Plasmodium vivax Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-04 Ric N Price
-
Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-04 Katharina Kocher, Carolin Moosmann, Felix Drost, Christine Schülein, Pascal Irrgang, Philipp Steininger, Jahn Zhong, Johannes Träger, Bernd Spriewald, Christoph Bock, Dirk H Busch, Christian Bogdan, Benjamin Schubert, Thomas H Winkler, Matthias Tenbusch, Ev-Marie Schuster, Kilian Schober
-
Is eradication of influenza B viruses possible? Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-04 Marios Koutsakos, Steven Rockman, Florian Krammer
-
Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study Lancet Infect Dis (IF 36.4) Pub Date : 2024-03-04 Marcelo Brito PhD, Rosilene Rufatto BSc, José Diego Brito-Sousa PhD, Felipe Murta PhD, Vanderson Sampaio PhD, Patrícia Balieiro MSc, Djane Baía-Silva PhD, Vanessa Castro BSc, Brenda Alves BSc, Aline Alencar MD, Stephan Duparc MD, Penny Grewal Daumerie MBA, Isabelle Borghini-Fuhrer PhD, Elodie Jambert PharmD, Cássio Peterka MSc, Francisco Edilson Lima Jr MSc, Leonardo Carvalho Maia BSc, Catherine Lucena
Prevention of malaria recurrence is essential for malaria elimination in Brazil. We evaluated the real-world effectiveness of an updated treatment algorithm for radical cure in the Brazilian Amazon. In this non-interventional observational study, we used retrospective data from the implementation of a treatment algorithm at 43 health facilities in Manaus and Porto Velho, Brazil. The treatment algorithm
-
Large language models must serve clinicians, not the reverse Lancet Infect Dis (IF 36.4) Pub Date : 2024-02-29 Richard Armitage
-
Revaccination with BCG: does it work? Lancet Infect Dis (IF 36.4) Pub Date : 2024-02-26 Helen McShane
-
Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial Lancet Infect Dis (IF 36.4) Pub Date : 2024-02-26 Paulo Cesar Pereira dos Santos MS, Nicole Louise Messina PhD, Prof Roberto Dias de Oliveira PhD, Patricia Vieira da Silva PhD, Marco Antonio Moreira Puga PhD, Margareth Dalcolmo PhD, Glauce dos Santos BSc, Marcus Vinícius Guimarães de Lacerda PhD, Bruno Araújo Jardim MSc, Fernando Fonseca de Almeida e Val PhD, Prof Nigel Curtis PhD, Prof Jason R Andrews MD, Julio Croda MD PhD
The effectiveness of BCG vaccine for adult pulmonary tuberculosis remains uncertain. In this study, we aimed to evaluate the effect of vaccination with BCG-Denmark to prevent initial and sustained interferon-γ release assay conversion in Brazilian health-care workers. This substudy is a nested randomised controlled trial embedded within the BRACE trial (). Specifically, this substudy enrolled Brazilian
-
Is a therapeutic dengue monoclonal antibody on the way? Lancet Infect Dis (IF 36.4) Pub Date : 2024-02-23 Eng Eong Ooi, Yvonne FZ Chan
-
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia Lancet Infect Dis (IF 36.4) Pub Date : 2024-02-23 Bhagwat Gunale MD, Nicholas Farinola BMBS, Chandrashekhar D Kamat PhD, Cyrus S Poonawalla DSc, Sambhaji S Pisal PhD, Rajeev M Dhere PhD, Claire Miller BA, Prasad S Kulkarni MD
Dengue is highly prevalent in Asia and Latin America and has no specific dengue antiviral treatment. A recombinant monoclonal antibody (VIS513) that neutralises all four serotypes of the dengue virus has been developed in India. After confirmation of safety and efficacy in preclinical studies, it was tested in a first-in-human study to assess the safety and pharmacokinetics. This was a partially blind
-
Quadrivalent dengue-virus vaccines: challenges and opportunities for India Lancet Infect Dis (IF 36.4) Pub Date : 2024-02-23 Guruprasad R Medigeshi, Farzana Islam, Rakesh Lodha
-
Malaria vaccine development in Mali: a step towards transmission-blocking strategies Lancet Infect Dis (IF 36.4) Pub Date : 2024-02-23 Amira Mohamed Taha, Dang Nguyen, Juan J Montenegro-Idrogo, Alfonso J Rodriguez-Morales
-
Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies – Authors' reply Lancet Infect Dis (IF 36.4) Pub Date : 2024-02-22 Christian Holm Hansen, Ida Rask Moustsen-Helms, Morten Rasmussen, Bolette Søborg, Henrik Ullum, Palle Valentiner-Branth
-
Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies Lancet Infect Dis (IF 36.4) Pub Date : 2024-02-22 Eero Poukka, Kari Auranen, Ulrike Baum